Fuelling innovation
Avedro, Inc has has secured $25 million in financing
Colin Kerr
Published: Friday, June 1, 2018
Avedro, Inc has announced that it has secured $25 million in financing led by Lilly Asia Ventures (LAV)
with major participation from existing investors OrbiMed Advisors, InterWest Partners and HealthQuest Capital.
“Avedro’s mission is to develop non-invasive corneal remodelling treatments that protect and improve vision and dramatically better patients’ lives,” said Reza Zadno, PhD, CEO of Avedro.
“This new funding brings together an exceptional syndicate of investors who are committed to helping us achieve this goal.”
www.Avedro.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.